Clinical Trials in Japan / NCT03314181
Active, not recruiting
Phase 2
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
NCT03314181 · tracked via the Priya Life Science Japan tracker
Condition(s) studied
Multiple Myeloma
Investigational drug(s) / intervention(s)
Dexamethasone: Infusion; Intravenous (IV), or Tablet; Oral
Daratumumab: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
Venetoclax: Tablet; Oral
Bortezomib: Injection; Subcutaneous (preferred), Infusion; Intravenous (IV)
Study summary
This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R) multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd); Part 3 includes participants with t(11;14) positive R/R multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd).
Part 1 and Part 2 are non-randomized and will be initiated with a dose-escalation phase in which increasing doses of venetoclax will be given with fixed doses of daratumumab and dexamethasone (Part 1a) or with fixed doses of daratumumab, bortezomib, and dexamethasone (Part 2a). Each dose escalation phase will be followed by a single-arm, open-label expansion phase. Part 3 will include a randomized, open-label expansion phase with participants receiving venetoclax in combination with daratumumab and dexamethasone (VenDd) or daratumumab, bortezomib, and dexamethasone (DVd).
Eligibility
Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) performance status \<= 2.
* Participant has relapsed or refractory multiple myeloma with documented evidence of progression that occurred during or after the participant's last treatment regimen based on investigator's determination of International Myeloma Working Group (IMWG) criteria.
* Measurable disease confirmed by central lab at Screening, defined by at least 1 of the following: Serum M-protein \>= 1.0 g/dL (\>= 10 g/L), OR Urine M-protein \>= 200 mg/24 hours, OR Serum free light chain (FLC) \>= 10 mg/dL, provided serum FLC ratio is abnormal in participants who do not have measurable disease by Serum Protein Electrophoresis (SPEP) or Urine Protein Electrophoresis (UPEP) criteria.
* Participant has received previous multiple myeloma treatment as defined in the protocol.
* Bone marrow aspirate samples have been collected.
* To qualify for Part 1 and 3, the participant must be t(11;14) positive as determined by an analytically validated Fluorescent In Situ Hybridization (FISH) assay per central laboratory testing.
* Participants must have adequate hematologic, renal and hepatic function.
Exclusion Criteria:
* Previous treatment with venetoclax or other B-Cell Lymphoma 2 (BCL-2) inhibitor
* For participants in Parts 1 and 2: Previous treatment with daratumumab or other anti-CD38 therapy. For participants in Part 3: Prior daratumumab or other anti-CD38 antibody therapy exposure that meets ANY of the following criteria:
* Failure to achieve at least a PR to most recent therapy with daratumumab or other anti-CD38 therapy.
* Daratumumab or other anti-CD38 antibody therapy was discontinued due to toxicity.
* Relapse within 60 days of intensive treatment (at least every other week) of daratumumab or other anti-CD38 antibody therapy.
* Prior treatment with daratumumab or other anti-CD38 antibody within 6 months prior to first dose of study drug.
* For participants in Part 2 and 3:
* Participant is refractory to any proteasome inhibitor, defined as progression on or within 60 days of the last dose of a proteasome inhibitor-containing regimen.
* Participant has had prior treatment with proteasome inhibitor within 60 days prior to first dose of study drug.
* Treatment with anti-myeloma chemotherapy, radiotherapy, biological, immunotherapy or an investigational therapy, including targeted small molecule agents within 2 weeks or 5 half-lives (whichever is longer and/or applicable) before first dose.
* Treatment with anti-myeloma monoclonal antibodies within 6 weeks prior to first dose.
* Recent corticosteroid therapy at a cumulative dose equivalent to \>= 140 mg of prednisone, cumulative dose equivalent to \>= 40 mg of dexamethasone, or a single dose equivalent to \>= 40 mg of dexamethasone within 2 weeks prior the first dose of study drug.
* Known central nervous system involvement of multiple myeloma.
* Significant history of medical conditions as listed in the protocol.
* History of other active malignancies including myelodysplatic syndromes (MDS) within the past 3 years with the exceptions of:
* Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin.
* Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment
* Previous malignancy with no evidence of disease confirmed and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study.
* Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
* Has a hypersensitivity or allergy to any of the components of study therapy, excipient or boron.
* Known allergies, hypersensitivities, or intolerance to monoclonal antibodies or human proteins, or their excipients, or known sensitivity to mammalian-derived products (see daratumumab prescribing information).
Primary outcome measure(s)
- Overall Response Rate (ORR) — Up to approximately 3.5 years after the last participant is enrolled
ORR is defined as the percentage of participants with documented partial response (PR) or better based on International Myeloma Working Group (IMWG) criteria. - Very Good Partial Response or Better Response Rate (VGPR) — Up to approximately 3.5 years after the last participant is enrolled
VGPR or better response rate is defined as the proportion of participants with documented VGPR or better (sCR, CR. or VGPR) based on IMWG criteria. - Complete Response (CR) or Better Rate — Up to approximately 3.5 years after the last participant is enrolled
CR or better response is defined as the percentage of participants with documented response of CR or better (stringent complete response \[sCR\] or CR) based on IMWG criteria. - Time to Response (TTR) — Up to approximately 3.5 years after the last participant is enrolled
TTR is defined as the number of days from the date of treatment start (for subjects enrolled prior to randomization start) or randomization (for randomized subjects) to the date of first documented response of PR or better. - Duration of Response (DOR) — Up to approximately 3.5 years after the last participant is enrolled
DOR is defined as the number of days from the participant's date of first documented response (PR or better) to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. - Time to Progression (TTP) — Up to approximately 3.5 years after the last participant is enrolled
TTP is defined as the number of days from the date of treatment start (for subjects enrolled prior to randomization start) or randomization (for randomized subjects) to the date of first documented PD or death due to MM, whichever occurs first. - Progression-Free Survival (PFS) — Up to approximately 3.5 years after the last participant is enrolled
PFS is defined as the number of days from the date of treatment start (for subjects enrolled prior to randomization start) or randomization (for randomized subjects) to the date of the first documented PD or death due to any cause, whichever occurs first. - Overall Survival (OS) — Up to approximately 3.5 years after the last participant is enrolled
OS is defined as the number of days from the date of treatment start (for subjects enrolled prior to randomization start) or randomization (for randomized subjects) to the date of death.
Trial sites (40)
| Facility | City | Region | Status |
|---|---|---|---|
| Univ of Colorado Cancer Center /ID# 167331 | Aurora | Colorado | |
| Moffitt Cancer Center /ID# 169614 | Tampa | Florida | |
| Winship Cancer Institute of Emory University /ID# 165427 | Atlanta | Georgia | |
| The University of Chicago Medical Center /ID# 165429 | Chicago | Illinois | |
| Beth Israel Deaconess Medical Center /ID# 210904 | Boston | Massachusetts | |
| Dana-Farber Cancer Institute /ID# 166886 | Boston | Massachusetts | |
| Hackensack Univ Med Ctr /ID# 225111 | Hackensack | New Jersey | |
| Duplicate_Roswell Park Comprehensive Cancer Center /ID# 169615 | Buffalo | New York | |
| Weill Cornell Medicine/NYP /ID# 167605 | New York | New York | |
| Atrium Health Carolinas Medical Center /ID# 164948 | Charlotte | North Carolina | |
| Duke Cancer Center /ID# 165104 | Durham | North Carolina | |
| Duplicate_Wake Forest Baptist Health /ID# 224447 | Winston-Salem | North Carolina | |
| Oregon Health and Science University /ID# 166822 | Portland | Oregon | |
| University of Washington /ID# 164884 | Seattle | Washington | |
| The Kinghorn Cancer Centre /ID# 165431 | Darlinghurst | New South Wales | |
| St George Hospital /ID# 171063 | Kogarah | New South Wales | |
| Duplicate_Royal Adelaide Hospital /ID# 171060 | Adelaide | South Australia | |
| Eastern Health /ID# 165850 | Box Hill | Victoria | |
| St Vincent's Hospital Melbourne /ID# 165853 | Fitzroy Melbourne | Victoria | |
| Peter MacCallum Cancer Ctr /ID# 164742 | Melbourne | Victoria | |
| Duplicate_Royal Perth Hospital /ID# 224895 | Perth | Western Australia | |
| Arthur J. E. Child Comprehensive Cancer Centre /ID# 167822 | Calgary | Alberta | |
| Cross Cancer Institute /ID# 203114 | Edmonton | Alberta | |
| Disc_Royal Victoria Hospital / McGill University Health Centre /ID# 167824 | Montreal | Quebec | |
| Rigshospitalet /ID# 164420 | Copenhagen Ø | Capital Region | |
| Duplicate_Aarhus University Hospital /ID# 164509 | Aarhus N | Central Jutland | |
| Odense University Hospital /ID# 164417 | Odense | Region Syddanmark | |
| Sygehus Lillebalt, Vejle /ID# 164418 | Vejle | Region Syddanmark | |
| CHU Limoges - Dupuytren 1 /ID# 224759 | Limoges | Franche-Comte | |
| CHRU Tours - Hopital Bretonneau /ID# 164795 | Tours | Indre-et-Loire | |
| Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 164767 | Nantes | Pays de la Loire Region | |
| Institut Gustave Roussy /ID# 164807 | Villejuif | Val-de-Marne | |
| CHU Poitiers - La miletrie /ID# 164806 | Poitiers | Vienne | |
| Duplicate_AP-HP - Hopital Saint-Louis /ID# 224758 | Paris | France | |
| Universitaetsklinikum Freiburg /ID# 166036 | Freiburg im Breisgau | Baden-Wurttemberg | |
| University Hospital Cologne /ID# 166037 | Cologne | North Rhine-Westphalia | |
| Nagoya City University Hospital /ID# 225273 | Nagoya | Aichi-ken | |
| Kameda General Hospital /ID# 225246 | Kamogawa-shi | Chiba | |
| Duplicate_Matsuyama Red Cross Hospital /ID# 225196 | Matsuyama | Ehime | |
| Gifu Municipal Hospital /ID# 240381 | Gifu | Gifu |
More AbbVie trials in Japan
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Active, not recruiting
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Active, not recruiting
Other trials for the same condition
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03314181 on ClinicalTrials.gov ↗ ← All trials in Japan